Skip to main content

Diuretika

  • Chapter
  • 466 Accesses

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   34.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003):The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571.

    Article  CAS  PubMed  Google Scholar 

  • Cosin J, Diez J, TORIC investigators (2003): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513.

    Google Scholar 

  • Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8: 105–120.

    Google Scholar 

  • Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7(Suppl 1): 81–85.

    PubMed  Google Scholar 

  • Greger R (1995): Loop Diuretics. In: Greger R, Knauf H, Mutschler, E (eds): Handbook of Experimental Pharmacology: Diuretics, Vol 117. Springer-Verlag, Berlin, pp 221–274.

    Google Scholar 

  • Heidland A, Bahner U (1999): Diuretika. In: Paumgartner G (Hrsg): Therapie innerer Krankheiten, 9. Aufl., Springer-Verlag, Berlin Heidelberg New York, S. 1548–1564.

    Google Scholar 

  • Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520.

    Article  CAS  PubMed  Google Scholar 

  • Noe LL, Vreelandmg, Pezzella SM, Trotter JP (1999): A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 21: 854–866.

    Article  CAS  PubMed  Google Scholar 

  • Oßwald H, Albinus M (1993): Hagers Handbuch der Pharmazeutischen Praxis, Stoffe A–Z, 5. Aufl, Band 8: Indapamid. In: von Bruchhausen F et al (Hrsg): S. 534–537, Band 9: Spironolacton, S. 650–654, Band 9: Xipamid S. 1212–1215. Springer-Verlag, Berlin.

    Google Scholar 

  • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.

    CAS  PubMed  Google Scholar 

  • Scheen aJ, Vancrombreucq JC, Delarge J, Luyckx AS (1986): Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 31(Suppl): 35–42.

    PubMed  Google Scholar 

  • Spannheimer A, Goertz A, Dreckmann-Behrendt B (1998): Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract 52: 467–471.

    CAS  PubMed  Google Scholar 

  • Stauch M, Stiehl L (1990): Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure — a multicenter study. Prog Pharmacol Clin Pharmacol 8: 121–126.

    Google Scholar 

  • Stroupe KT, Forthofer MM, Brater DC, Murray MD (2000): Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 17: 429–440.

    CAS  PubMed  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2003). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.

    Google Scholar 

  • Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995): Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57: 601–609.

    Article  CAS  PubMed  Google Scholar 

  • Wilcox CS (2002): New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol 13: 798–805.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Oßwald, H., Mühlbauer, B. (2006). Diuretika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2005. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30505-X_25

Download citation

  • DOI: https://doi.org/10.1007/3-540-30505-X_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28368-3

  • Online ISBN: 978-3-540-30505-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics